Amanta Healthcare IPO
Ahmedabad-based pharmaceutical firm Amanta Healthcare Limited is set to tap the capital markets with its Initial Public Offering (IPO) opening on Monday, September 1, 2025. The company aims to raise ₹126 crore through a complete fresh issue of shares to fund significant expansion of its manufacturing capabilities. The issue will close for subscription on Wednesday, September 3, 2025.
Amanta Healthcare IPO Details
The IPO is a book-built issue comprising a fresh issuance of 1,00,00,000 equity shares, with a price band fixed at ₹120 to ₹126 per share. For retail investors, the minimum application is for one lot of 119 shares, translating to an investment of ₹14,994 at the upper price band. The company’s shares are proposed to be listed on both the BSE and NSE, with a tentative listing date of Tuesday, September 9, 2025.
Amanta Healthcare IPO Objectives
The net proceeds from the IPO are earmarked primarily for capital expenditure to enhance the company’s manufacturing infrastructure at its Hariyala, Gujarat plant. Of the proceeds, ₹70.00 crore will be used for setting up a new manufacturing line for SteriPort, and ₹30.13 crore is designated for establishing a new manufacturing line for SVP (Small Volume Parenterals). The remaining funds will be utilized for general corporate purposes. This strategic investment underscores the company’s focus on scaling up production to meet growing demand.
Company Incorporation and Financial Details
Incorporated in 1994, Amanta Healthcare specializes in the development and manufacturing of sterile liquid pharmaceutical products, including IV fluids, ophthalmic solutions, and respiratory care products, using advanced Aseptic Blow-Fill-Seal (ABFS) technology. The company’s financial performance shows a remarkable turnaround in profitability. For the financial year ending March 31, 2025, while total income saw a slight 2% dip to ₹276.09 crore, the Profit After Tax (PAT) surged by an impressive 189% to ₹10.50 crore from ₹3.63 crore in the previous year. This follows a loss in FY23, indicating a strong recovery and improved operational efficiency, alongside a consistent reduction in total borrowings.
Amanta Healthcare IPO Reservation
The issue has a reservation structure with not more than 50% allocated for Qualified Institutional Buyers (QIB), not less than 35% for Retail Individual Investors (RII), and not less than 15% for Non-Institutional Investors (NII). Beeline Capital Advisors Pvt. Ltd. is the book-running lead manager for the issue, while MUFG Intime India Pvt. Ltd. is the registrar. Allotment of shares is expected to be finalized by September 4, 2025.